Amarin Corp Plc (AMRN)

[HDGabor]

Hi Kiwi,

Short summary:

“[Note: Sealed] Information regarding product launch planning is manifestly confidential business information. Amarin’s request to make public … of this nature is especially troubling”. – AZN’s argument on 09/11/2014 Doc #21. (I agree with AZN.)

AZN has 2 arguments:

1.) Epanova does not infringe the patent, since change from baseline is greater than 20% – “funny”, the patent is “against baseline or placebo” and diff. is less than 20% compared with placebo.
2.) Epanova is not on the market

I do not know the exact claim of AMRN, but the ruling could be:

- Dismissal
- AZN will be restricted to market Epanova